Bispecific antibodies for treatment of cancer in experimental animal models and man

Advanced Drug Delivery Reviews

Volumn 31, Issue 1-2, 1998, Pages 105-129

  Kroesen, B J ^a   Helfrich, W ^a   Molema, G ^a   De Leij, L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bispecific antibodies; Cancer; Cytolytic activity; Immune effector cell activation; Immune effector cell targeting; Immunotherapy; Macrophage; NK cell; T cell

Indexed keywords

CYTOLOGY; DRUG DOSAGE; MONOCLONAL ANTIBODIES; ONCOLOGY; PHYSIOLOGICAL MODELS;

BISPECIFIC ANTIBODIES;

CONTROLLED DRUG DELIVERY;

BISPECIFIC ANTIBODY; CANCER ANTIBODY; CYTOKINE; FAS LIGAND; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOTOXIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CHEMICAL ENGINEERING; CHILL; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; DYSPNEA; EFFECTOR CELL; FLU LIKE SYNDROME; GENETIC ENGINEERING; HUMAN; NATURAL KILLER CELL; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RASH; T LYMPHOCYTE; VOMITING;

EID: 0032489898     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00096-3     Document Type: Review

References (211)

1. Waldmann T.A. Monoclonal antibodies in diagnosis and therapy. Science. 252:1991;1657-1662.
2. Mellstedt H., Frodin J.E., Masucci G., Ragnhammer P., Fagerberg J., Hjelm A.L., Shetye J., Wersall P., Osterborg A. The therapeutic use of monoclonal antibodies in colorectal carcinoma. Sem. Oncol. 18:1991;462-477.
3. Steffens T.A., Bajorin D.F., Houghton A.N. Immunotherapy with monoclonal antibodies in metastatic melanoma. World J. Surg. 16:1992;261-269.
4. Mellstedt H., Frodin J.E., Masucci G. Clinical status of monoclonal antibodies in the treatment of colorectal carcinoma. Oncology. 3:1989;25-32.
5. Herlyn D., Sears H., Iliopoulos D., Lubeck M., Douillard J.Y., Sindelar W., Tempero M., Mellstedt H., Maher M., Koprowski H. Anti-idiotypic antibodies to monoclonal antibody CO17-1A. Hybridoma. 5:1986;51-58.
6. Milstein C., Cuello A.C. Hybrid hybridomas and their use in immunohistochemistry. Nature. 305:1983;537-540.
7. Jung G., Ledbetter J.A., Muller-Eberhard H.J. Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. Proc. Natl. Acad. Sci. U.S.A. 84:1987;4611-4615.
8. Jung G., Freimann U., Von Marschall Z., Reisfeld R.A., Wilmanns W. Target cell-induced T cell activation with bi- and trispecific antibody fragments. Eur. J. Immunol. 21:1991;2431-2435.
9. Kroesen B.J., Bakker A., van Lier R.A.W., The T.H., De Leij L. Bispecific antibody-mediated target cell-specific costimulation of resting T cells via CD5 and CD28. Cancer Res. 55:1995;4409-4415.
10. Valone F.H., Kaufman P.A., Fanger M.W., Guyre P.M. Bispecific monoclonal antibody therapy (anti HER-2/neu×Anti CD 64) for human breast cancers that overexpress HER-2/neu. J. Cell. Biochem. Suppl. 17/G:1920;255.
11. Simone C.B. Directed effector cells selectively lyse human tumour cells. Nature. 297:1982;234-236.
12. Tutt A., Greenman J., Stevenson G.T., Glennie M.J. Bispecific F(ab′gamma)3 antibody derivatives for redirecting unprimed cytotoxic T cells. Eur. J. Immunol. 21:1991;1351-1358.
13. Haagen I.A., van de Griend R., Clark M., Geerars A., Bast B., de Gast B. Killing of leukemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (CD3×CD19). Clin. Exp. Immunol. 90:1992;368-375.
14. Nitta T., Sato K., Yagita H., Okumura K., Ishii S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet. 335:1990;368-371.
15. Ferrini S., Prigione I., Mammoliti S., Colnaghi M.I., Menard S., Moretta A., Moretta L. Re-targeting of human lymphocytes expressing the T-cell receptor gamma/delta to ovarian carcinoma cells by the use of bispecific monoclonal antibodies. Int. J. Cancer. 44:1989;245-250.
16. Ferrini S., Cambiaggi A., Sforzini S., Canevari S., Mezzanzanica D., Colnaghi M.I., Moretta L. Use of anti-CD3 and anti-CD16 bispecific monoclonal antibodies for the targeting of T and NK cells against tumor cells. Cancer Detect. Prev. 17:1993;295-300.
17. Garcia de Palazzo I., Holmes M., Gercel-Taylor C., Weiner L.M. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16. Cancer Res. 52:1992;5713-5719.
18. Greenman J., Tutt A.L., George A.J., Pulford K.A., Stevenson G.T., Glennie M.J. Characterization of a new monoclonal anti-Fc gamma RII antibody, AT10, and its incorporation into a bispecific F(ab′)2 derivative for recruitment of cytotoxic effectors. Mol. Immunol. 28:1991;1243-1254.
19. de Lau W.J.M., van Loon A.E., Heije K., Valerio D., Bast B.J. Production of hybrid hybridomas on HAT sensitive neomicin resistant double mutants. J. Immunol. 117:1989;1-8.
20. Perez P., Hoffman R.W., Shaw S., Bluestone J.A., Segal D.M. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature. 316:1985;354-356.
21. Karpovsky B., Titus J.A., Stephany D.A., Segal D.M. Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies. J. Exp. Med. 160:1984;1686-1701.
22. Brennan M., Davison P.E., Pualus H. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science. 229:1985;81.
23. Glennie M.J., McBride H.M., Worth A.T., Stevenson G.T. Preparation and performance of bispecific F(ab′)2 antibody containing thioether-linked Fab′ fragments. J. Immunol. 139:1987;2367.
24. Tutt A., Stevenson G.T., Glennie M.J. Trispecific F(ab′)3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells. J. Immunol. 147:1991;60-69.
25. Carter P., Ridgway J., Zhu Z. Toward the production of bispecific antibody fragments for clinical applications. J. Hematother. 4:1995;463-470.
26. Borrebaeck C.A.K., Malmborg A.C., Ohlin M. Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics? Immunol. Today. 14:1993;477-479.
27. Wettendorff M., Iliopoulos D., Tempero M., Kay D., DeFreitas E., Koprowski H., Herlyn D. Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A. Proc. Natl. Acad. Sci. U.S.A. 86:1989;3787-3791.
28. Zhu Z., Carter P. Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation. J. Immunol. 155:1995;1903-1910.
29. Kurucz I., Titus J.A., Jost C.R., Segal D.M. Correct disulfide pairing and efficient refolding of detergent-solubilized single-chain Fv protein from bacterial inclusion bodies. Mol. Immunol. 32:1995;1443-1452.
30. Jost C.R., Titus J.A., Kurucz I., Segal D.M. A single-chain bispecific Fv-2 molecule produced in mammalian cells redirects lysis by activated CTL. Mol. Immunol. 33:1996;211-219.
31. Zhu Z., Zapata G., Shalaby R., Snedecor B., Chen H., Carter P. High level secretion of a humanized bispecific diabody from Escherichia coli. Bio/Technology. 14:1996;192-196.
32. Jost C.R., Kurucz I., Jacobus C.M., Titus J.A., George A.J.T., Segal D.M. Mammalian expression and secretion of functional single-chain Fv molecules. J. Biol. Chem. 269:1994;26267-26273.
33. Johnson K.S., Chiswell D.J. Human antibody engineering. Curr. Biol. 3:1993;564-571.
34. Adams G.P., McCartney J.E., Tai M.S., Oppermann H., Huston J.S., Stafford W.F., Bookman M.A., Fand I., Houston L.L., Weiner L.M. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res. 53:1993;4026-4034.
35. McCafferty J., Griffiths A.D., Winter G., Chiswell D.J. Phage antibodies: Filamentous phage displaying antibody variable domains. Nature. 348:1990;552-554.
36. Nissim A., Hoogenboom H.R., Tomlinson I.M., Flynn G., Midgley C., Lane D., Winter G. Antibody fragments from a "single pot" phage display library as immunochemical reagents. EMBO J. 13:1994;692-698.
37. Green L.L., Hardy M.C., Maynard Currie C.E., Tsuda H., Louie D.M., Mendez M.J., Abderrahim H., Noguchi M., Smith D.H., Zeng Y. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat. Genet. 7:1994;13-21.
38. Cumber A.J., Ward E.S., Winter G., Parnell G.D., Wawrzynczak E.J. Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugate. J. Immunol. 149:1992;120-126.
39. Mallender W.D., Voss E.W. Jr. Construction, expression, and activity of a bivalent bispecific single-chain antibody. J. Biol. Chem. 269:1994;199-206.
40. Mack M., Riethmuller G., Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 92:1995;7021-7025.
41. Gruber M., Schodin B.A., Wilson E.R., Kranz D.M. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J. Immunol. 152:1994;5368-5374.
42. Kostelny S.A., Cole M.S., Tso J.Y. Formation of a bispecific antibody by the use of leucine zippers. J. Immunol. 148:1992;1547-1553.
43. Tso J.Y., Wang S.L., Levin W., Hakimi J. Preparation of a bispecific F(ab′)2 targeted to the human IL-2 receptor. J. Hematother. 4:1995;389-394.
44. Holliger P., Prospero T., Winter G. Diabodies: Small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. U.S.A. 90:1993;6444-6448.
45. Perisic O., Webb P.A., Holliger P., Winter G., Williams R.L. Crystal structure of a diabody, a bivalent antibody fragment. Structure. 2:1994;1217-1226.
46. Holliger P., Brissinck J., Williams R.L., Thielemans K., Winter G. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng. 9:1996;299-305.
47. Rodrigues M.L., Presta L.G., Kotts C.E., Wirth C., Mordenti J., Osaka G., Wong W.L., Nuijens A., Blackburn B., Carter P. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res. 55:1995;63-70.
48. De Leij L. Tumor and differentiation antigens. Encyclopedia of Cancer. 1:1997;1818-1839.
49. Demanet C., Brissinck J., De Jonge J., Thielemans K. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation. Blood. 87:1996;4390-4398.
50. Link B.K., Weiner G.J. Production and characterization of a bispecific IgG capable of inducing T-cell-mediated lysis of malignant B cells. Blood. 81:1993;3343-3349.
51. Elsasser D., Valerius T., Repp R., Weiner G.J., Deo Y., Kalden J.R., van de Winkel J.G., Stevenson G.T., Glennie M.J., Gramatzki M., Link B.K. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood. 87:1996;3803-3812.
52. Hendler F.J., Ozanne B.W. Human squamous cell lung cancers express increased epidermal growth factor receptor. J. Clin. Invest. 74:1984;647-651.
53. Berger M.S., Gullick W.J., Greenfield C. Epidermal growth factor receptors in lung tumors. J. Pathol. 52:1987;297-307.
54. Tateishi M., Ishida T., Mitsudomi T., Sugimachi K. Immunohistochemical evidence of autocrine factors in adenocarcinoma of the human lung. Cancer Res. 50:1990;7077-7080.
55. Schneider P.M., Hung M.C., Chiocca S.M. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res. 49:1989;4968-4971.
56. Weiner D.B., Nordberg J., Robinson R. Expression of the neu gene-encoding protein (p185neu) in human non-small cell lung cancer. Cancer Res. 50:1990;5184-5191.
57. Mezzanzanica D., Canevari S., Colnaghi M.I. Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic. Int. J. Clin. Lab. Res. 21:1991;159-164.
58. Mezzanzanica D., Canevari S., Menard S., Pupa S.M. Human ovarian carcinoma lysis by cytotoxic T cells. Int. J. Cancer. 41:1988;609-615.
59. Mezzanzanica D., Garrido M.A., Neblock D.S., Daddona P.E., Andrew S.M., Zurawski V.R. Jr., Segal D.M., Wunderlich J.R. Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab′)2 antibody prolong host survival in a murine xenograft model. Cancer Res. 51:1991;5716-5721.
60. Tibben J.G., Boerman O.C., Claessens R.A., Corstens F.H., van Deuren M., de Mulder P.H., Van der Meer J.W., Keijser K.G., Massuger L.F. Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab′)2 [letter]. J. Natl. Cancer Inst. 85:1993;1003-1004.
61. Bolhuis R.L.H., Lamers C.H.J., Goey S.H. Adoptive immunotherapy of ovarian carcinoma with Bs-Mab-targeted lymphocytes: a multicentre study. Int. J. Cancer. S7:1992;78-81.
62. Miotti S., Canevari S., Menard S., Mezzanzanica D., Porro G. Characterization of human ovarian carcinoma-associated. Int. J. Cancer. 39:1987;297-303.
63. Momburg F., Moldenhauer G., Hammerling G.J., Moller P. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res. 47:1987;2883-2891.
64. Edwards D.P., Grzyb K.T., Dressler L.G., Mansel R.E., Zava D.T., Sledge G.W., McGuire W.L. Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer. Cancer Res. 46:1986;1306-1317.
65. Varki N.M., Reisfeld R.A., Walker L.E. Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies. Cancer Res. 44:1984;681-687.
66. Bumol T.F., Marder P., van de Herdt S., Borowitz M.J., Apelgren L.D. Characterization of the human tumor and normal tissue reactivity of the KS1/4 monoclonal antibody. Hybridoma. 7:1988;407-415.
67. Spurr N.K., Durbin H., Sheer D., Parkar M., Bobrow L. Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUAI. Int. J. Cancer. 38:1986;631-636.
68. Linnenbach A.J., Wojcierowski J., Wu S.A., Pyrc J.J., Ross A.H. Sequence investigation of the major gastrointestinal tumor associated antigen gene family, GA733. Proc. Natl. Acad. Sci. U.S.A. 86:1989;27-31.
69. Litvinov S.V., Velders M.P., Bakker H.A.M., Fleuren G.J. Ep-CAM: A human epithelial antigen is a homophilic cell-cell adhesion molecule. J. Cell Biol. 125:1994;437-446.
70. Sforzini S., Bolognesi A., Meazza R., Marciano S., Tazzari P.L., Stein H., Stirpe F., Ferrini S. Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies. J. Hematother. 4:1995;429-432.
71. Duke-Cohan J.S., Morimoto C., Schlossman S.F. Depletion of the helper/inducer (memory) T cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD29. Transplantation. 56:1993;1188-1196.
72. Flavell D.J., Cooper S., Morland B., French R., Flavell S.U. Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target molecules. Br. J. Cancer. 65:1992;545-551.
73. Bonardi M.A., French R.R., Amlot P., Gromo G., Modena D., Glennie M.J. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing. Cancer Res. 53:1993;3015-3021.
74. French R.R., Courtenay A.E., Ingamells S., Stevenson G.T., Glennie M.J. Cooperative mixtures of bispecific F(ab′)2 antibodies for delivering saporin to lymphoma in vitro and in vivo. Cancer Res. 51:1991;2353-2361.
75. French R.R., Bell A.J., Hamblin T.J., Tutt A.L., Glennie M.J. Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin. Lancet. 346:1995;223-224.
76. Goodwin D.A., Meares C.F., McCall M.J., McTigue M., Chaovapong W. Pre-targeted immunoscintigraphy of murine tumours with indium 111-labeled bifunctional haptens. J. Nucl. Med. 29:1988;226-234.
77. le Doussal J.M., Gruaz-Guyon A., Martin M., Gautherot E., Delaage M., Barbet J. Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res. 50:1990;3445-3452.
78. Liu L., Barth R.F., Adams D.M., Soloway A.H., Reisfeld R.A. Bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. J. Hematother. 4:1995;477-483.
79. Hattori K., Tsukamoto H., Ohta S., Yabe M., Yabe H., Kato S., Takakura I., Ueda R., Habu S., Nishimura T. Bispecific antibody-mediated cytotoxicity by CD4+ and CD8+-activated T cells generated from leukemia patients after allogeneic bone marrow transplantation. Bone Marrow Transplant. 15:1995;193-198.
80. Nitta T., Yagita H., Azuma T., Sato K., Okumura K. Bispecific F(ab′)2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells. Eur. J. Immunol. 19:1989;1437-1441.
81. Ferrini S., Prigione I., Miotti S., Ciccone E., Cantoni C., Chen Q., Colnaghi M.I., Moretta L. Bispecific monoclonal antibodies directed to CD16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones. Int. J. Cancer. 48:1991;227-233.
82. Staerz U.D., Bevan M.J. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc. Natl. Acad. Sci. U.S.A. 83:1986;1453-1457.
83. Lanzavecchia A., Scheidegger D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur. J. Immunol. 17:1987;105-111.
84. Fanger M.W., Shen L., Graziano R.F., Guyre P.M. Cytotoxicity mediated by human Fc receptors for IgG. Immunol. Today. 10:1989;92-99.
85. van de Winkel J.G., Capel P.J. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol. Today. 14:1993;215-221.
86. van Vugt M.J., Heijnen A.F., Capel P.J., Park S.Y., Ra C., Saito T., Verbeek J.S., van de Winkel J.G. FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo. Blood. 87:1996;3593-3599.
87. Guyre P.M., Graziano R.F., Vance B.A., Morganelli P.M., Fanger M.W. Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function. J. Immunol. 143:1989;1650-1655.
88. Valerius T., Repp R., de Wit T.P., Berthold S., Platzer E., Kalden J.R., Gramatzki M., van de Winkel J.G. Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood. 82:1993;931-939.
89. Valone F.H., Kaufman P.A., Guyre P.M., Lewis L.D., Memoli V., Ernstoff M.S., Wells W., Barth R., Deo Y., Fisher J. Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. J. Hematother. 4:1995;471-475.
90. Valone F.H., Kaufman P.A., Guyre P.M., Lewis L.D., Memoli V., Deo Y., Graziano R., Fisher J.L., Meyer L., Mrozek Orlowski M. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J. Clin. Oncol. 13:1995;2281-2292.
91. Phillips J.H., Takeshita T., Sugamura K., Lanier L.L. Activation of natural killer cells via the p75 interleukin 2 receptor. J. Exp. Med. 170:1989;291.
92. Umehara H., Bloom E.T. The IL-2 receptor beta subunit is absolutely required for mediating the IL-2-induced activation of NK activity and proliferative activity of human large granular lymphocytes. Immunology. 70:1990;111-115.
93. Vitolo D., Vujanovic N.L., Rabinowich H., Schlesinger M., Herverman R.B., Whiteside T.L. Rapid IL-2-induced adherence of human natural killer cells. Expression of mRNA for cytokines and IL-2 receptors in adherent NK cells. J. Immunol. 151:1993;1926-1937.
94. Sahin U., Kraft Bauer S., Ohnesorge S., Pfreundschuh M., Renner C. Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors. Cancer Immunol. Immunother. 42:1996;9-14.
95. Renner C., Pfreundschuh M. Tumor therapy by immune recruitment with bispecific antibodies. Immunol. Rev. 145:1995;179-209.
96. Bottino C., Sivori S., Vitale M., Cantoni C., Falco M., Pende D., Morelli L., Augugliaro R., Semenzato G., Biassoni R., Moretta L., Moretta A. A novel surface molecule homologous to the p58/p50 family of receptors is selectively expressed on a subset of human natural killer cells and induces both triggering of cell functions and proliferation. Eur. J. Immunol. 7:1995;67-73.
97. Weiner L.M., Holmes M., Adams G.P., LaCreta F., Watts P., Garcia de Palazzo I. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res. 53:1993;94-100.
98. DePalazzo G.I., Gercel-Taylor C., Kitson J., Weiner L. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc III receptor expressed by human large granular lymphocytes. Cancer Res. 52:1990;7123-7128.
99. Weiner L.M., Clark J.I., Ring D.B., Alpaugh R.K. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. J. Hematother. 4:1995;453-456.
100. Phillips J.H., Lanier L.L. Lectin-dependent and anti-CD3 induced cytotoxicity are preferentially mediated by peripheral blood cytotoxic T lymphocytes expressing Leu-7 antigen. J. Immunol. 136:1986;1579.
101. Azuma M., Cayabyab M., Buck D., Phillips J.H., Lanier L.L. CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J. Exp. Med. 175:1992;353-360.
102. de Jong R., Brouwer M., Rebel V.I., van Seventer G.A., Miedema F., van Lier R.A.W. Generation of alloreactive cytolytic T lymphocytes by immobilized anti-CD3 monoclonal antibodies. Analysis of requirements for human cytolytic T-lymphocyte differentiation. Immunology. 70:1990;357.
103. Bach F.H., Geller R.L., Nelson P.J., Panzer S., Gromo G., Benfield M.R., Inverardi L., Podack E.R., Witson J.C., Houchins J.P. A 'minimal signal-stepwise activation' analysis of functional maturation of T lymphocytes. Immunol. Rev. 111:1989;35-57.
104. Kuiper H.M., de Jong R., Brouwer M., Lammers K. Influence of CD28 co-stimulation on cytokine production is mainly regulated via interleukin-2. Immunology. 83:1909;38.
105. Lindsten T., June C.H., Ledbetter J.A., Stella G., Thompson C.B. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science. 244:1989;339-343.
106. Cerdan C., Martin Y., Courcoul M., Brailly H., Mawas C., Birg F., Olive D. Prolonged IL-2 receptor alpha/CD25 expression after T cell activation via the adhesion molecules CD2 and CD28: Demonstration of combined transcriptional and post-transcriptional regulation. J. Immunol. 149:1992;2255-2261.
107. Ceuppens J.L., Baroja M.L. Monoclonal antibodies to the CD5 antigen can provide the necessary second signal for activation of isolated resting T cells by solid-phase-bound OKT3. J. Immunol. 137:1986;1816-1821.
108. van Seventer G.A., Shimizu Y., Horgan K.J., Shaw S. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J. Immunol. 144:1990;4579-4586.
109. Braakman E., Kuijpers K.C., de Jong R., Jaspars E.H., Lucas C.J. Generation of cell-mediated cytotoxicity in vitro. Dev. Biol. Stand. 69:1988;169-175.
110. de Jong R., Stokkers P., Lamme E., Kool J.M., Borst F., Brouwer M., Miedema F., van Lier R.A. Regulation of T-cell differentiation by CD2 and CD28 accessory molecules. Immunology. 74:1991;175-182.
111. Geller R.L. Role of cross-linking in stepwise activation of T cells. Scand. J. Immunol. 35:1992;327-334.
112. Garcia-penarrubia P., Bankhurst A.D. Kinetic analysis of effector cell recycling and effector target binding capacity in a model of cell-mediated cytotoxicity. J. Immunol. 143:1989;2101-2111.
113. Staerz U.D., Kanagawa O., Bevan M.J. Hybrid antibodies can target sites for attack by T cells. Nature. 314:1985;628-631.
114. Renner C., Jung W., Sahin U., Denfeld R., Pohl C., Trumper L., Hartmann F., Diehl V., van Lier R., Pfreundschuh M. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science. 264:1994;833-835.
115. Maas R.A., Dullens H.F.J., Den Otter W. Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol. Immunother. 36:1993;141-148.
116. Rubin J.T., Elwood L.J., Rosenberg S.A., Lotze M.T. Immunohistochemical correlates of response to recombinant interleukin-2 based immunotherapy in humans. Cancer Res. 49:1989;7086-7092.
117. Abubakr Y.A., Chou T.H., Redman B.G. Spontaneous remission of renal cell carcinoma: a case report and immunological correlates. J. Urol. 152:1994;156-157.
118. Swoboda R., Bommhardt U., Schimpl A. Regulation of lymphokine expression in T cell activation. I. Rapid loss of interleukin-specific RNA after removal of the stimulating signal. Eur. J. Immunol. 21:1991;1691-1695.
119. Qian J.H., Titus J.A., Andrew S.M., Mezzanzanica D., Garrido M.A., Wunderlich J.R., Segal D.M. Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth. J. Immunol. 146:1991;3250-3256.
120. Beun G.D.M., Gorter A., Nooyen Y., van de velde C.J.H., Fleuren G.J. T cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model. (II) Syngeneic colon carcinoma CC531 is efficiently killed by retargeted cytotoxic T-lymphocytes in vitro despite limited lysis in 51Cr release assays. J. Immunol. 150:1993;2305-2315.
121. Segal D.M., Qian J.H., Titus J.A., Moreno M.B., George A.J., Jost C.R., Kurucz I., el-Gamil M., Wunderlich J.R. Targeted cytokine production. Int. J. Cancer Suppl. 7:1992;36-38.
122. Beun G.D.M., van de velde C.J.H., Fleuren G.J. T cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model. (III) Activation of resting T cells and tumor neutralization induced by bispecific antibodies. J. Immunother. 13:1993;223-231.
123. Hoon D.S., Hayashi Y., Morisaki T., Foshag L.J., Morton D.L. Interleukin-4 plus tumor necrosis factor alpha augments the antigenicity of melanoma cells. Cancer Immunol. Immunother. 37:1993;378-384.
124. Kroesen B.J., Wellenberg G., Bakker A., Helfrich W., The T.H., De Leij L. The role of apoptosis in bispecific antibody-mediated T-cell cytotoxicity. Br. J. Cancer. 73:1995;721-727.
125. Curnow S.J., Glennie M.J., Stevenson G.T. The role of apoptosis in antibody-dependent cellular cytotoxicity. Cancer Immunol. Immunother. 36:1993;149-155.
126. Haagen I.A., Geerars A.J., De Lau W.B., Bast B.J., de Gast B.C. The efficacy of CD3×CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2. Blood. 85:1995;3208-3212.
127. Blank-Voorthuis C.J.A.C., Braakman E., Ronteltap C.P.M., Tilly B.C., Sturm E., Warnaar S.O., Bolhuis R.L.H. Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by cytotoxic T lymphocytes via CD3. J. Immunol. 151:1993;2904-2914.
128. Viola A., Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science. 273:1996;104-106.
129. Valitutti S., Muller S., Cella M., Padovan E., Lanzavecchia A. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature. 375:1995;148-151.
130. Sloan Lancaster J., Shaw A.S., Rothbard J.B., Allen P.M. Partial T cell signaling: Altered phospho-zeta and lack of Zap70 recruitment in APL-induced T cell anergy. Cell. 79:1994;913-922.
131. Donohue J.H., Ramsey P.S., Kerr L.A., Segal D.M., McKean D.J. Enhanced in vitro lysis of human ovarian carcinomas with activated peripheral blood lymphocytes and bifunctional immune heteroaggregates. Cancer Res. 50:1990;6508-6514.
132. Kerr L., Huntoon C., Donohue J., Leibson P.J., Bander N.H., Ghose T., Luner S.J., Vessella R., McKean D.J. Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes. J. Immunol. 144:1990;4060-4067.
133. Jung G., Martin D.E., Muller-Eberhard H.J. Induction of cytotoxicity in human peripheral blood mononuclear cells by monoclonal antibody OKT3. J. Immunol. 139:1987;639-644.
134. van Wauwe J.P., Goossens J.G., Beverley P.C.L. Human T lymphocyte activation by monoclonal antibodies; OKT3, but not UCHT1, triggers mitogenesis via an interleukin 2-dependent mechanism. J. Immunol. 133:1984;129-132.
135. Pupa S.M., Canevari S., Fontanelli R., Menard S., Mezzanzanica D., Lanzavecchia A., Colnaghi M.I. Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells. Int. J. Cancer. 42:1988;455-459.
136. Hirsch R., Gress R.E., Pluznik D.H., Eckhaus M., Bluestone J.A. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J. Immunol. 142:1989;737-743.
137. Ellenhorn J.D.I., Hirsch R., Schreiber H., Bluestone J.A. In vivo administration of anti-CD3 prevents malignant progressor tumor growth. Science. 242:1988;569-571.
138. Ferran C., Sheehan K., Dy M., Schreiber R., Merite S., Landais P., Noel L.H., Grau G., Bluestone J., Bach J.F. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur. J. Immunol. 20:1990;509-515.
139. Sosman J.A., Weiss G.R., Margolin K.A., Aronson F.R., Sznol M., Atkins M.B., O'Boyle K., Fisher S.G., Mier J., Vachino G., Caliendo G. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: Clinical and immunologic effects. J. Clin. Oncol. 11:1993;1496-1505.
140. Buter J., Janssen R.A.J., Martens A., Sleijfer D.T., De Leij L., Mulder N.H. Phase I/II study of low dose intravenous OKT3 and subcutaneous interleukin-2 in metastatic cancer. Eur. J. Cancer. 29A:1993;2108-2113.
141. Ellenhorn J.D., Woodle E.S., Ghobreal I., Thistlethwaite J.R., Bluestone J.A. Activation of human T cells in vivo following treatment of transplant recipients with OKT3. Transplantation. 50:1990;608-612.
142. Chatenoud L., Ferran C., Reuter A. Systemic reaction to the anti T cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and IFN alpha. New. Engl. J. Med. 320:1989;1420-1421.
143. Chatenoud L., Ferran C., Legendre C., Thouard I., Merite S., Reuter A., Gevaert Y., Kreis H., Franchimont P., Bach J.F. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation. 49:1990;697-702.
144. Janssen R.A.J., Heijn A.A., The T.H., De Leij L. Poor induction of IL-2R expression on CD8 bright cells in whole blood cell cultures with CD3 mAb. Implications for immunotherapy with CD3 mAb. Cancer Immunol. Immunother. 38:1994;53-60.
145. Weiner G.J., Kostelny S.A., Hillstrom J.R., Cole M.S., Link B.K., Wang S.L., Tso J.Y. The role of T cell activation in anti-CD3×antitumor bispecific antibody therapy. J. Immunol. 152:1994;2385-2392.
146. Penna C., Dean P.A., Nelson H. antitumor×anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enteroxin B to neutralize pulmonary metastases. Cancer Res. 54:1994;2738-2743.
147. Penna C., Dean P.A., Nelson H. Pulmonary metastases neutralization and tumor rejection by in vivo administration of beta glucan and bispecific antibody. Int. J. Cancer. 65:1996;377-382.
148. Roosnek E.E., van Lier R.A., van Aarden L.A. Two monoclonal anti-CD3 antibodies can induce different events in human T lymphocyte activation. Eur. J. Immunol. 17:1987;1507.
149. Bohlen, H., Manzke, O., Titzer, S., Engert, A., Wolf, J., Diehl, V., Tesch, H., Treatment of EB-virus induced B-cell LCL in SCID-HU mice using CD3×CD19 bispecific and CD28 antibodies. Proceedings of the 58th Am. Assoc. 10-13 April, 1994, San Francisco, USA, Cancer Res. (AACR), 1994, abstract 3041.
150. Janssen R.A.J., Kroesen B.J., Buter J., Mesander G., Sleijfer D.T., The T.H., Mulder N.H., De Leij L. Immunomodulatory effects of intravenous BIS-1 F(ab′)2 administration in renal cell cancer patients. Br. J. Cancer. 72:1995;795-799.
151. Nieken, J., Kroesen, B.J., Groen, H., De Leij, L., Mulder, N.H., Phase I trial of IL-2 plus repetitive doses of bispecific monoclonal antibody BIS-1 F(ab′)2. Proc. 88th Am. Assoc. 12-16 April, 1997, San Diego, USA, Cancer Res. (AACR), 1997.
152. De Gast G.C., Van Houten A.A., Haagen I.A., Klein S., De Weger R.A., Van Dijk A., Phillips J., Clark M., Bast B.J. Clinical experience with CD3×CD19 bispecific antibodies in patients with B cell malignancies. J. Hematother. 4:1995;433-437.
153. Costello R., Lipcey C., Algarte M., Cerdan C., Baeuerle P.A., Olive D., Imbert J. Activation of primary human T-lymphocytes through CD2 plus CD28 adhesion molecules induces long-term nuclear expression of NF-kappa B. Cell Growth Differ. 4:1993;329-339.
154. Vandenberghe P., Verwilghen J., van Vaeck F., Ceuppens J.L. Ligation of the CD5 or CD28 molecules on resting human T cells induces expression of the early activation antigen CD69 by a calcium- and tyrosine kinase-dependent mechanism. Immunology. 78:1993;210-217.
155. Verwilghen J., Vandenberghe P., Wallays G., de Boer M., Anthony N., Panayi G.S., Ceuppens J.L. Simultaneous ligation of CD5 and CD28 on resting T lymphocytes induces T cell activation in the absence of T cell receptor/CD3 occupancy. J. Immunol. 150:1993;835-846.
156. Bachmann M.F., Sebzda E., Kundig T.M., Shahinian A., Speiser D.E., Mak T.W., Ohashi P.S. T cell responses are governed by avidity and co-stimulatory thresholds. Eur. J. Immunol. 26:1996;2017-2022.
157. Kundig T.M., Shahinian A., Kawai K., Mittrucker H.W., Sebzda E., Bachmann M.F., Mak T.W., Ohashi P.S. Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity. 5:1996;41-52.
158. Titus J.A., Perez P., Kaubisch A., Garrido M.A., Segal D.M. Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J. Immunol. 139:1987;3153-3158.
159. Demanet C., Brissinck J., Van Mechelen M., Leo O., Thielemans K. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype×anti-CD3). J. Immunol. 147:1991;1091-1097.
160. Weiner G.J., Hillstrom J.R. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J. Immunol. 147:1991;4035-4044.
161. Belani R., Weiner G.J. T cell activation and cytokine production in anti-CD3 bispecific antibody therapy. J. Hematother. 4:1995;395-402.
162. Kroesen B.J., Helfrich W., Bakker A., Wubbena A.S., Bakker H., Kal H.B., The T.H., De Leij L. Reduction of EGP-2-positive pulmonary metastases by bispecific-antibody-redirected T cells in an immunocompetent rat model. Int. J. Cancer. 61:1995;812-818.
163. Beun G.D.M., van de velde C.J.H., Fleuren G.J., Eggermont A.M.M. T cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model. (IV) Tumor neutralization in a Winn type assay. J. Immunother. 14:1993;11-15.
164. Urra J.M., Peces R., Martinez-Naves E., Gutierrez V., Setien F., Lopez-Larrea C. Tumor necrosis factor alpha is released by monocytes in OKT3 monoclonal antibody immunosuppressive therapy. Transplant. Proc. 24:1992;2542-2544.
165. Abramowicz D., Schandene L., Goldman M., Kinnaert P., Dupont E., Toussaint C. Release of tumor necrosis factor, interleukin-2 and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation. 47:1989;606-608.
166. Demanet C., Brissinck J., Moser M., Leo O., Thielemans K. Bispecific antibody therapy of two murine B-cell lymphomas. Int. J. Cancer Suppl. 7:1992;67-68.
167. Kroesen B.J., Buter J., Sleijfer D.T., Janssen R.A.J., van der Graaf W., The T.H., De Leij L., Mulder N.H. Phase I study of intravenously applied bispecific antibody in patients receiving subcutaneous IL-2. Br. J. Cancer. 70:1994;652-661.
168. Kroesen B.J., ter Haar A., Spakman H., Willemse P., Sleijfer D.T., de Vries E.G., Mulder N.H., Berendsen H.H., Limburg P.C., The T.H., De Leij L. Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol. Immunother. 37:1993;400-407.
169. Canevari S., Mezzanzanica D., Mazzoni A., Negri D.R., Ramakrishna V., Bolhuis R.L., Colnaghi M.I., Bolis G. Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. J. Hematother. 4:1995;423-427.
170. Ball E.D., Guyre P.M., Mills L., Fisher J., Dinces N.B., Fanger M.W. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: Cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (Moab PM81) and anti-CD64/Fc RI (Moab 32). J. Hematother. 1:1992;85-94.
171. Repp R., Valerius T., Wieland G., Becker W., Steininger H., Deo Y., Helm G., Gramatzki M., van de Winkel J.G., Lang N. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210). J. Hematother. 4:1995;415-421.
172. Kroesen B.J., Janssen R.A.J., Buter J., Nieken J., Sleijfer D.T., Mulder N.H., De Leij L. Bispecific antibodies for intravenous treatment of carcinoma patients: Immunobiological aspects. J. Hematother. 4:1995;409-414.
173. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 76:1994;301-314.
174. Ratner S. Lymphocyte migration through extracellular matrix. Invasion Metastasis. 12:1992;82-100.
175. May M.J., Ager A. ICAM-1-independent lymphocyte transmigration across high endothelium: differential up-regulation by interferon gamma, tumor necrosis factor-alpha and interleukin 1 beta. Eur. J. Immunol. 22:1992;219-226.
176. Christopher E.M., Griffiths M.B., Voorhees J.J., Nickoloff B.J. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: Modulation by recombinant gamma interferon and tumor necrosis factor. J. Am. Acad. Dermatol. 20:1988;617-629.
177. Cotran R.S., Pober J.S., Gimbrone M.A. Jr., Springer T.A., Wiebke E.A., Gaspari A.A., Rosenberg S.A., Lotze M.T. Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J. Immunol. 139:1987;1883-1888.
178. Ratner S., Patrick P., Bora G. Lymphocyte development of adherence and motility in extracellular matrix during IL-2 stimulation. J. Immunol. 149:1992;681-688.
179. Janssen R., Jongsma J., Noteboom J., Kroesen B.J., Helfrich W., Kal H., The H., De Leij L. Interleukin-2 enhances T lymphocyte migration to the tumor site. Proc. Am. Assoc. Cancer Res. 34:1993;486.
180. Lissoni P., Barni S., Cattaneo G., Archili C., Crispino S., Tancini G., D'Angelo L., Magni S., Fiorelli G. Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leak syndrome. Int. J. Biol. Markers. 5:1990;195-197.
181. Ratner S. Lymphocytes stimulated with recombinant human interleukin-2: relationship between motility into protein matrix and in vivo localization in normal and neoplastic tissues of mice. J. Natl. Cancer Inst. 82:1990;612-616.
182. Melder R.J., Koenig G.C., Witwer B.P., Safabakhsh N., Munn L.L., Jain R.K. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium [see comments]. Nat. Med. 2:1996;992-997.
183. Renard N., Lienard D., Lespagnard L., Eggermont A., Heimann R., Lejeune F. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF-α). Int. J. Cancer. 57:1994;656-663.
184. Griffioen A.W., Damen C.A., Blijham G.H., Groenewegen G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood. 88:1996;667-673.
185. Minasian L., Szatrowski T., Rosenblum M., Steffens T., Morrison M., Chapman P., Williams L., Nathan C., Houghton A. Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-α and anti-GD3 ganglioside monoclonal antibody in patients with etastatic melanoma. Blood. 83:1994;56-64.
186. Bajorin D.F., Chapman P.B., Wong G.Y., Cody B.V., Cordon Cardo C., Dantes L., Templeton M.A., Scheinberg D., Oettgen H.F., Houghton A.N. Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. Melanoma Res. 2:1992;355-362.
187. Bozic C.R., Lu B., Hopken U.E., Gerard C., Gerard N.P. Neurogenic amplification of immune complex inflammation. Science. 273:1996;1722-1725.
188. Canevari S., Stoter G., Arienti F., Bolis G., Colnaghi M.I., Di Re E.M., Eggermont A.M., Goey S.H., Gratama J.W., Lamers C.H. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl. Cancer Inst. 87:1995;1463-1469.
189. Brissinck J., Demanet C., Moser M., Leo O., Thielemans K. Bispecific antibodies in lymphoma. Int. Rev. Immunol. 10:1993;187-194.
190. Herlyn D., Wettendorf M., Koprowski H. Modulation of cancer patients' immune responses by anti-idiotypic antibodies. Int. Rev. Immunol. 4:1989;347-357.
191. Morimoto C., Rudd C.E., Letvin N.L., Schlossman S.F. A novel epitope of the LFA-1 antigen which can distinguish killer effector and suppressor cells in human CD8 cells. Nature. 330:1987;479-482.
192. Tsubota H., Lord C.I., Watkins D.I., Morimoto C., Letvin N.L. A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes. J. Exp. Med. 169:1989;1421-1434.
193. Hviid L., Theander T.G., Abdulhadi N.H., Abu-Zeid Y.A., Bayoumi R.A., Jensen J.B. Transient depletion of T cells with high LFA-1 expression from peripheral circulation during acute Plasmodium falciparum malaria. Eur. J. Immunol. 21:1991;1249-1253.
194. Bergelson L.D. Serum gangliosides as endogenous immunomodulators. Immunol. Today. 16:1995;483-486.
195. Olshefski R., Taylor B., Heitger A., Hasegawa A., Ladisch S. Induction of programmed cell death and immunosuppression by exogenous sphingolipids are separate processes. Eur. J. Biochem. 241:1996;47-55.
196. Gimmi C.D., Morrison B.W., Mainprice B.A., Gribben J.G., Boussiotis V.A., Freeman G.J., Young-Lee-Park S., Watanabe M., Gong J., Hayes D.F., Kufe L.M., Nadler L.M. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat. Med. 2:1996;1367-1370.
197. Lu P., Sharom F.J. Immunosuppression by YAC-1 lymphoma: Role of shed gangliosides. Cell. Immunol. 173:1996;22-32.
198. Lu P., Sharom F.J. Gangliosides are potent immunosuppressors of IL-2-mediated T-cell proliferation in a low protein environment. Immunology. 86:1995;356-363.
199. Nakagomi H., Petersson M., Magnusson I., Juhlin C., Matsuda M., Mellstedt H., Taupin J.L., Vivier E., Anderson P., Kiessling R. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 53:1993;5610-5612.
200. Alexander J.P., Kudoh S., Melsop K.A., Hamilton T.A., Edinger M.G., Tubbs R.R., Sica D., Tuason L., Klein E., Bukowski R.M., Finke J.H. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res. 53:1993;1380-1387.
201. Renner C., Ohnesorge S., Held G., Bauer S., Jung W., Pfitzenmeier J.P., Prfeundschuh M. T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood. 88:1996;236-241.
202. Strand S., Hofmann W.J., Hug H., Muller M.D., Mariani S.M., Stremmel W., Krammer P.H., Galle P.R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion? Nat. Med. 2:1996;1361-1366.
203. Gosselin E.J., Wardwell K., Gosselin D.R., Alter N., Fisher J.L., Guyre P.M. Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens. J. Immunol. 149:1992;3477-3481.
204. Johnson B.E. Management of small-cell lung cancer. Clin. Chest Med. 14:1993;173-187.
205. Bonardi M.A., Bell A., French R.R., Gromo G., Hamblin T., Modena D., Tutt A.L., Glennie M.J. Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin. Int. J. Cancer Suppl. 7:1992;73-77.
206. Chetanneau A., Barbet J., Peltier P., le Doussal J.M., Gruaz Guyon A., Bernard A.M., Resche I., Rouvier E., Bourguet P., Delaage M. Pretargetted imaging of colorectal cancer recurrences using an 111In-labelled bivalent hapten and a bispecific antibody conjugate. Nucl. Med. Commun. 15:1994;972-980.
207. le Doussal J.M., Chetanneau A., Gruaz Guyon A., Martin M., Gautherot E., Lehur P.A., Chatal J.F., Delaage M., Barbet J. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. J. Nucl. Med. 34:1993;1662-1671.
208. Ferrini S., Cambiaggi A., Cantoni C., Canevari S., Mezzanzanica D., Colnaghi M.I., Moretta L. Targeting of T or NK lymphocytes against tumor cells by bispecific monoclonal antibodies: role of different triggering molecules. Int. J. Cancer Suppl. 7:1992;15-18.
209. Hombach A., Jung W., Pohl C., Renner C., Sahin U., Schmits R., Wolf J., Kapp U., Diehl V., Pfreundschuh M. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int. J. Cancer. 55:1993;830-836.
210. Ely P., Wallace P.K., Givan A.L., Graziano R.F., Guyre P.M., Fanger M.W. Bispecific-armed, interferon gamma-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma. Blood. 87:1996;3813-3821.
211. Wallace P.K., Howell A.L., Fanger M.W. Role of Fc gamma receptors in cancer and infectious disease. J. Leukocyte Biol. 55:1994;816-826.